Aprepitant
규격
170729-80-3CAS 번호
677-636-6EC 번호
3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-oneIUPAC 명칭
C23H21F7N4O3화학식
534.4 g/mol분자량
Aprepitant; 170729-80-3; MK-869; MK-0869; Cinvanti; Aponvie; L-754030; ONO-7436; aprepitantum; DTXSID3049047; 1NF15YR6UY; NSC-748825; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; L-754,030; CHEBI:499361; DTXCID801021794; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-; 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(Trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; 3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,4-dihydro-; 3-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholin-4-yl)methyl)-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-; 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholin-4-yl)methyl)-1,2-dihydro-1,2,4-triazol-3-one; RefChem:57104; A04AD12; MK869; 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-3H-1,2,4-Triazol-3-one; MK0517; L754030; L754,030; L 754,030; 677-636-6; Emend; 5-[2(R)-[1(R)-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY]-3(S)-(4-FLUOROPHENYL)MORPHOLIN-4-YLMETHYL]-3,4-DIHYDRO-2H-1,2,4-TRIAZOL-3-ONE; MFCD08277635; L 754030; CHEMBL1471; C23H21F7N4O3; 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one; 321125-94-4; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-3(2H)-one; Aprepitant [USAN]; 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-5(4H)-one; 5-[(2R,3S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one; 5-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,3-dihydro-1H-1,2,4-triazol-3-one; CAS-170729-80-3; Emend (TN); Aprepitant (MK-0869); MK 869; UNII-1NF15YR6UY; MK 0869; eMende; Aprepitant [USAN:INN:JAN]; Aprepitant`; Aprepitant CRS; NCGC00181785-01; Cinvanti (TN); 5-[[(2R,3S)-2-[(R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-3(2H)-one; aprepitant, form I; Aponvie (TN); aprepitant, form II; MK0869; Aprepitant Impurity I; Aprepitant (Standard); APREPITANT [MI]; APREPITANT [INN]; APREPITANT [JAN]; APREPITANT [VANDF]; APREPITANT [MART.]; APREPITANT [USP-RS]; APREPITANT [WHO-DD]; Aprepitant (JAN/USP/INN); MLS006011068; APREPITANT [EMA EPAR]; SCHEMBL264924; SCHEMBL280611; Aprepitant - Bio-X trade mark; GTPL3490; orb1225953; orb1307556; SCHEMBL7117513; APREPITANT [ORANGE BOOK]; APREPITANT [EP MONOGRAPH]; EX-A212; APREPITANT [USP MONOGRAPH]; GLXC-05008; HMS2090N12; HMS3714E16; HMS3884G05; ONO 7436; Tox21_113595; BDBM50220136; EBC-11285; EBC-27288; HY-10052R; NSC748825; AKOS015895498; AKOS015969344; Tox21_113595_1; CCG-220747; CCG-264854; CS-0487; DB00673; FA17962; NSC 748825; NCGC00181785-03; NCGC00181785-04; NCGC00181785-11; NCGC00181785-12; NCGC00344566-01; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; AS-14638; BA164216; HY-10052; SMR002530053; SY027654; Aprepitant (MK-0869, L-754030)?; A6368; Aprepitant,MK-0869, L-754030, Emend; C21555; D02968; EN300-761455; SBI-0654102.0001; AB01274775-01; AB01274775_02; AB01275535-01; F862381; SR-05000001531; SR-05000001531-1; BRD-K52827117-001-01-6; Z2937147473; Aprepitant, United States Pharmacopeia (USP) Reference Standard; 3-(((2R,3S)-3-(P-FLUOROPHENYL)-2-(((.ALPHA.R)-.ALPHA.-METHYL-3,5-BIS(TRIFLUOROMETHYL)BENZYL)OXY)MORPHOLINO)METHYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONE.; 3-[((2R,5-bis(trifluoromethyl)benzyl]oxy}morpholino)methyl]-.delta.2-1,2,4-triazolin-5-one; 3-[[(2R,3S)-2-[(1R)-1-bis(Trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4dihydro-1,2,4-triazol-5-one; 3-[2-{1-[3,5-di(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-1,4-oxazinan-4-ylmethyl]-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2R-(2alpha(R*),3alpha))-; 3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, rel-; 3H-1,2,4-Triazol-3-one,5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-,rel-; 3H-1,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1,2-dihydro-3H-1,2,4-triazol-3-one; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2H-1,2,4-triazol-3(4H)-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol- 3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-1,2-dihydro-3H-1,2,4-triazol-3-one동의어
Aprepitant 함유 제품
아탄트캡슐125밀리그램(아프레피탄트)아탄트캡슐80밀리그램(아프레피탄트)에멘드캡슐125밀리그램(아프레피탄트)에멘드캡슐80밀리그램(아프레피탄트)アプレピタントカプセル80mg「NK」/アプレピタントカプセル125mg「NK」/アプレピタントカプセルセット「NK」アプレピタントカプセル125mg「サワイ」/アプレピタントカプセル80mg「サワイ」/アプレピタントカプセルセット「サワイ」EMEND 80 MG CAPSULAS DURASAPREPITANT QILU 80 MG CAPSULAS DURAS EFGAPREPITANT QILU 125 MG CAPSULAS DURAS EFGAPREPITANT QILU 125 MG CAPSULAS DURAS/ APREPITANT QILU 80 MG CAPSULAS DURAS EFGAPREPITANT ACCORD 125 MG CAPSULAS DURAS EFG/APREPITANT ACCORD 80 MG CAPSULAS DURAS EFGEMEND 125 MG POLVO PARA SUSPENSION ORAL
1/5 페이지
Aprepitant 판매 기업
SQ
SICHUAN QINGMU PHARMACEUTICAL CO.,LTD.ChinaVP
Viwit Pharmaceutical Co., Ltd.ChinaTE
TIANJIN ENJU BIOTECHNOLOGY CO., LTD.ChinaWP
Wisdom Pharmaceutical Co.,Ltd.ChinaPB
Pure Bio Medical Jiangsu Co.LtdChinaVS
VIATRIS SANTEFranceSF
Sandoz Farmaceutica S.A.SpainSA
SANDOZFrance1/3 페이지